Literature DB >> 29209574

CARs on a highway with roadblocks.

Lorenzo Galluzzi1,2,3, Peter Martin4.   

Abstract

Keywords:  KYMRIAH™; acute lymphoblastic leukemia; chimeric antigen receptor; gene therapy; immunotherapy; tisagenlecleucel

Year:  2017        PMID： 29209574      PMCID： PMC5706598          DOI： 10.1080/2162402X.2017.1388486

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  21 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 2.  Clinical development of oncolytic viruses in China.

Authors:  Min Liang
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

3.  Fine-tuning the CAR spacer improves T-cell potency.

Authors:  Norihiro Watanabe; Pradip Bajgain; Sujita Sukumaran; Salma Ansari; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

4.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

Review 5.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

6.  CAR T-cells: an exciting frontier in cancer therapy.

Authors: 
Journal:  Lancet       Date:  2017-09-09       Impact factor: 79.321

Review 7.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Authors:  James N Kochenderfer; Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

8.  Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Authors:  John M Pagel; Howard Jack West
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777

Review 9.  Driving CAR T-cells forward.

Authors:  Hollie J Jackson; Sarwish Rafiq; Renier J Brentjens
Journal:  Nat Rev Clin Oncol       Date:  2016-03-22       Impact factor: 66.675

10.  CAR-T cells are serial killers.

Authors:  Alexander J Davenport; Misty R Jenkins; David S Ritchie; H Miles Prince; Joseph A Trapani; Michael H Kershaw; Phillip K Darcy; Paul J Neeson
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110
View more
  4 in total

Review 1.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 2.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

3.  Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.

Authors:  Cornelia Fischer; Michael W Munks; Ann B Hill; Richard A Kroczek; Stefan Bissinger; Verena Brand; Martina Schmittnaegel; Sabine Imhof-Jung; Eike Hoffmann; Frank Herting; Christian Klein; Hendrik Knoetgen
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

4.  Understanding cell culture dynamics: a tool for defining protocol parameters for improved processes and efficient manufacturing using human embryonic stem cells.

Authors:  J W T Kusena; M Shariatzadeh; R J Thomas; S L Wilson
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.